Krystal Biotech Inc expected to post earnings of 58 cents a share - Earnings Preview

Krystal Biotech

02/08/2024 17:01

* Krystal Biotech Inc  KRYS.OQ   KRYS.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 5
for the period ending June 30 2024
    * The Pittsburgh Pennsylvania-based  company is expected to
report
revenue of $65.335 million, according to the mean estimate from
8 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Krystal Biotech Inc is
for
earnings of 58 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Krystal
Biotech
Inc is $195.00​, below​ its last closing price of $198.78. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  0.15        0.15       0.03      Missed  -79.6
 Dec. 31 2024  -0.42       -0.42      0.30      Beat    170.6
 Sep. 30 2023  -0.32       -0.29      -0.69     Missed  -141.3
                                                        ​
 Jun. 30 2023  -0.69       -0.74      -1.25     Missed  -69.7
 ​​Mar.        -1.43       -1.44      -1.76     Missed  -22.3
 31 2023                                                
 Dec. 31 2022  -1.31       -1.32      -1.25     Beat    5.4​
 Sep. 30 2022  -1.23       -1.22      -1.17     Beat    3.9
 Jun. 30 2022  -0.99       -1.02      -1.10     Missed  -8.3
 This summary was machine generated August 2 at 16:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)